Truist Financial Corp lowered its holdings in shares of Encompass Health Co. (NYSE:EHC – Free Report) by 89.1% during the 4th quarter, HoldingsChannel reports. The fund owned 26,648 shares of the company’s stock after selling 218,599 shares during the period. Truist Financial Corp’s holdings in Encompass Health were worth $1,778,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. International Assets Investment Management LLC purchased a new stake in Encompass Health during the 4th quarter valued at about $20,210,000. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Encompass Health by 2.3% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,318,784 shares of the company’s stock valued at $87,989,000 after buying an additional 29,926 shares during the last quarter. Phocas Financial Corp. increased its position in shares of Encompass Health by 112.4% during the fourth quarter. Phocas Financial Corp. now owns 99,875 shares of the company’s stock valued at $6,664,000 after acquiring an additional 52,847 shares in the last quarter. Nordea Investment Management AB raised its holdings in Encompass Health by 21.0% in the 4th quarter. Nordea Investment Management AB now owns 101,705 shares of the company’s stock worth $6,787,000 after acquiring an additional 17,684 shares during the last quarter. Finally, Oak Thistle LLC lifted its position in Encompass Health by 19.1% in the 4th quarter. Oak Thistle LLC now owns 14,436 shares of the company’s stock valued at $963,000 after acquiring an additional 2,319 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on EHC. Raymond James restated a “strong-buy” rating and issued a $95.00 price target (up previously from $85.00) on shares of Encompass Health in a research note on Friday, April 26th. Truist Financial upped their target price on shares of Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Friday, February 9th. William Blair reiterated an “outperform” rating on shares of Encompass Health in a research note on Wednesday, February 7th. Royal Bank of Canada restated an “outperform” rating and set a $83.00 price objective on shares of Encompass Health in a research report on Friday, February 9th. Finally, Stephens reiterated an “overweight” rating and set a $85.00 target price on shares of Encompass Health in a research note on Tuesday, January 16th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $90.29.
Read Our Latest Research Report on Encompass Health
Insider Activity
In related news, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the completion of the transaction, the chief executive officer now directly owns 554,098 shares of the company’s stock, valued at $46,139,740.46. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the completion of the transaction, the chief executive officer now directly owns 554,098 shares in the company, valued at approximately $46,139,740.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP John Patrick Darby sold 14,543 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $83.94, for a total transaction of $1,220,739.42. Following the completion of the transaction, the executive vice president now directly owns 84,773 shares of the company’s stock, valued at $7,115,845.62. The disclosure for this sale can be found here. Company insiders own 2.10% of the company’s stock.
Encompass Health Stock Up 0.2 %
Shares of EHC stock opened at $86.53 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.14. Encompass Health Co. has a 12 month low of $57.55 and a 12 month high of $86.72. The stock has a market cap of $8.71 billion, a P/E ratio of 23.39, a P/E/G ratio of 1.32 and a beta of 0.92. The company has a 50 day simple moving average of $80.00 and a two-hundred day simple moving average of $72.15.
Encompass Health (NYSE:EHC – Get Free Report) last posted its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.93 by $0.19. The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.27 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. Encompass Health’s revenue was up 13.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.88 EPS. On average, research analysts expect that Encompass Health Co. will post 4.1 earnings per share for the current year.
Encompass Health Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Monday, July 1st will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.69%. The ex-dividend date is Friday, June 28th. Encompass Health’s dividend payout ratio (DPR) is presently 16.22%.
About Encompass Health
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Read More
Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Co. (NYSE:EHC – Free Report).
Receive News & Ratings for Encompass Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Encompass Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
